$1.25 Billion is the total value of FRAZIER MANAGEMENT LLC's 35 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 22.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $305,003,000 | +2.8% | 10,542,790 | 0.0% | 24.46% | +7.1% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $218,878,000 | +13.1% | 5,827,415 | 0.0% | 17.56% | +17.8% | |
| PASG | PASSAGE BIO INC | $87,561,000 | -31.6% | 5,009,219 | 0.0% | 7.02% | -28.8% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $70,696,000 | +13.5% | 3,566,912 | 0.0% | 5.67% | +18.2% | |
| KRYS | KRYSTAL BIOTECH INC | $68,951,000 | +28.4% | 895,000 | 0.0% | 5.53% | +33.7% | |
| TARS | TARSUS PHARMACEUTICALS INC | $61,790,000 | -22.0% | 1,917,157 | 0.0% | 4.96% | -18.8% | |
| PCVX | VAXCYTE INC | $45,614,000 | -25.7% | 2,309,554 | 0.0% | 3.66% | -22.6% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $41,570,000 | -31.8% | 1,312,999 | 0.0% | 3.33% | -28.9% | |
| TBIO | TRANSLATE BIO INC | $35,994,000 | -10.5% | 2,182,789 | 0.0% | 2.89% | -6.8% | |
| Buy | TRILLIUM THERAPEUTICS INC | $33,419,000 | -25.5% | 3,123,107 | +2.3% | 2.68% | -22.5% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $32,088,000 | +2.7% | 1,435,045 | +2.1% | 2.57% | +7.0% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $27,257,000 | -15.9% | 2,571,450 | 0.0% | 2.19% | -12.4% | |
| STRO | SUTRO BIOPHARMA INC | $22,792,000 | +4.8% | 1,001,421 | 0.0% | 1.83% | +9.2% | |
| ANAB | ANAPTYSBIO INC | $19,389,000 | +0.2% | 899,700 | 0.0% | 1.56% | +4.4% | |
| ACRS | New | ACLARIS THERAPEUTICS INC | $17,539,000 | – | 696,000 | +100.0% | 1.41% | – |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $17,340,000 | +119.3% | 1,374,047 | +63.2% | 1.39% | +128.4% |
| ISEE | Buy | IVERIC BIO INC | $15,725,000 | -8.8% | 2,544,500 | +2.0% | 1.26% | -5.0% |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $15,250,000 | -2.1% | 1,501,000 | 0.0% | 1.22% | +1.9% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $14,169,000 | -9.0% | 1,437,028 | 0.0% | 1.14% | -5.3% | |
| RGNX | Buy | REGENXBIO INC | $12,005,000 | -22.6% | 351,954 | +2.9% | 0.96% | -19.3% |
| GRTS | Sell | GRITSTONE ONCOLOGY INC | $9,721,000 | +19.7% | 1,030,878 | -50.0% | 0.78% | +24.6% |
| APTX | APTINYX INC | $9,570,000 | -13.3% | 3,190,079 | 0.0% | 0.77% | -9.6% | |
| EPIX | New | ESSA PHARMA INC | $9,198,000 | – | 316,616 | +100.0% | 0.74% | – |
| IMVT | New | IMMUNOVANT INC | $8,148,000 | – | 508,000 | +100.0% | 0.65% | – |
| SRRK | Buy | SCHOLAR ROCK HLDG CORP | $7,903,000 | +6.1% | 156,000 | +1.6% | 0.63% | +10.5% |
| FRLN | FREELINE THERAPEUTICS HLDGSsponsored ads | $6,765,000 | -32.6% | 550,000 | 0.0% | 0.54% | -29.8% | |
| EPZM | Buy | EPIZYME INC | $6,440,000 | -18.9% | 739,369 | +1.1% | 0.52% | -15.5% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $5,226,000 | – | 578,104 | +100.0% | 0.42% | – |
| BLU | BELLUS HEALTH INC NEW | $4,948,000 | +26.9% | 1,296,743 | 0.0% | 0.40% | +32.3% | |
| ALNA | ALLENA PHARMACEUTICALS | $4,629,000 | +8.6% | 3,330,373 | 0.0% | 0.37% | +13.1% | |
| SRRA | SIERRA ONCOLOGY INC | $3,494,000 | +7.5% | 202,803 | 0.0% | 0.28% | +12.0% | |
| CRDF | Sell | CARDIFF ONCOLOGY INC | $2,718,000 | -73.4% | 293,500 | -48.4% | 0.22% | -72.3% |
| ITRM | ITERUM THERAPEUTICS PLC | $2,169,000 | +42.6% | 1,538,316 | 0.0% | 0.17% | +48.7% | |
| GRTX | GALERA THERAPEUTICS INC | $2,126,000 | -13.8% | 241,000 | 0.0% | 0.17% | -10.0% | |
| NABRIVA THERAPEUTICS PLC | $707,000 | -31.4% | 425,650 | 0.0% | 0.06% | -27.8% | ||
| NERV | Exit | MINERVA NEUROSCIENCES INC | $0 | – | -61,541 | -100.0% | -0.01% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -35,750 | -100.0% | -0.13% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -168,000 | -100.0% | -0.71% | – |
| COLL | Exit | COLLEGIUM PHARMACEUTICAL INC | $0 | – | -943,666 | -100.0% | -1.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.